Case reportPublished 2017
Cutaneous Toxicity from Epidermal Growth Factor Receptor Inhibitors: A Report of Two Cases
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Epidermal growth factor inhibitors are currently an essential treatment for many advance-stage epithelial cancers as colorectal and lung cancer. Although they are safe, these agents often present cutaneous adverse events that can cause dosage reduction, interruption of treatment and psychosocial discomfort. We report two cases of cutaneous toxicity in patients with solid tumors using different epidermal growth factor inhibitors.
Subjects
Genetics & Molecular BiologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalMolecular and Genetic Medicine
- SubjectGenetics & Molecular Biology
- BylineArticles whose byline prints “Rosa VDL”
- BylineArticles whose byline prints “Marota EP”
- BylineArticles whose byline prints “Da Mata JC”
- BylineArticles whose byline prints “Sampaio MM”
- BylineArticles whose byline prints “De Oliveira JR”
